Cite
HARVARD Citation
Werth, B. et al. (2018). Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clinical microbiology and infection. pp. 429.e1-429.e5. [Online].